Advances in the development of new biologics in inflammatory bowel disease

Biologics have revolutionized the therapeutic approach in inflammatory bowel disease (IBD). Anti-tumor necrosis factor (anti-TNF) agents infliximab and adalimumab currently constitute the major biological therapy in IBD. Additional anti-TNFs such as golimumab and other new biologics are currently be...

Descripción completa

Detalles Bibliográficos
Autores principales: Ungar, Bella, Kopylov, Uri
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hellenic Society of Gastroenterology 2016
Materias:
Invited Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4923809/
https://www.ncbi.nlm.nih.gov/pubmed/27366024
http://dx.doi.org/10.20524/aog.2016.0027

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4923809/
https://www.ncbi.nlm.nih.gov/pubmed/27366024
http://dx.doi.org/10.20524/aog.2016.0027

Ejemplares similares